Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction
- 91 Downloads
Atrial fibrillation (AF) worsens cardiovascular (CV) outcomes of heart failure (HF) and vice versa. The impact of rate or rhythm control strategies on HF progression and survival remains unclear.
We examined the risk of HF progression in AF patients (pts) with a prior HF event and minimal or no HF burden (NYHA class 0 or 1). They were stratified into HF with a preserved left ventricular ejection fraction (≥ 40%, pEF) or reduced EF (< 40%, rEF). HF subgroups from the Rate and Rhythm arm were compared for the primary outcome of worsening HF or death (WHFD), total mortality, cardiovascular mortality, and cardiovascular hospitalizations.
Four hundred ninety-two AF pts (HFpEF = 349, HFrEF = 143) were analyzed. Baseline characteristics were generally comparable in the Rate and Rhythm arms of the two subgroups. Over a median follow-up of 4 years, HF recurred and worsened in 66.6% and 41.2% of pts by ≥ 1 and ≥ 2 NYHA classes, respectively. HF progression by even 1 NYHA class increased the mortality risk in HFpEF (hazard ratio (HR) 2.06; 95% confidence intervals (CI) 1.25–3.4; p = 0.004) and HFrEF (HR 1.9; 95% CI 0.99–3.66; p = 0.054). Cardiovascular hospitalization (CVH) increased in HFpEF (HR 3.67; 95% CI 2.56, 5.25; p < 0.0001) and HFrEF (HR 2.8; 95% CI 1.53–5.14; p = 0.0009). HF progression by 2 or more NYHA classes or death was significantly worse in pts with HFrEF with the Rate control strategy compared with the Rhythm control (HR 1.62; 95% CI 1.03–2.53; p = 0.036) but similar in pts with HFpEF (HR 0.88; 95% CI 0.64–1.21; p = 0.440).The time to first AF recurrence was longer in the Rhythm arms of both HF subgroups as compared with Rate (Figure, p < 0.05).
(1) HF progression in AF pts with a prior HF event confers significant mortality and CVH risk in both HFrEF and HFpEF populations. (2) HF progression is more pronounced with a Rate control strategy in AF pts with HFrEF, but is comparable to Rhythm control in AF pts with HFpEF. (3) A Rhythm control strategy may be desirable to reduce HF progression in pts with HFrEF and AF. Prospective clinical trials appear warranted to examine HF progression by treatment strategy in HFpEF and HFrEF populations with AF.
KeywordsAtrial fibrillation Heart failure Clinical trials Rhythm control Outcomes research Heart failure with preserved systolic function
This research study was funded by the Electrophysiology Research Foundation, Warren, NJ.
- 3.Saksena S, Slee A, Waldo AL, Freemantle N, Reynolds M, Rosenberg Y, et al. Cardiovascular outcomes in the AFFIRM trial (atrial fibrillation follow-up investigation of rhythm management): an assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol. 2011;58:1975–85.CrossRefGoogle Scholar
- 11.Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray J, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47(10):1997–2004.CrossRefGoogle Scholar
- 13.Saksena S, Slee A, Nagarakanti R. Impact of sinus rhythm restoration on cardiovascular outcomes in atrial fibrillation is influenced by quantitative rather than qualitative achievement of sinus rhythm and antiarrhythmic drug selection. Heart Rhythm. 2013;10(5, May Supplement):S390 PO05–73.Google Scholar
- 15.Nagarakanti R, Saksena S, Hettrick D, Koehler JL, Grammatico A, Padeletti L. Progression of new onset to established persistent atrial fibrillation: an implantable device-based analysis with implications for clinical classification of persistent atrial fibrillation. J Interv Card Electrophysiol. 2011;32(1):7–15. https://doi.org/10.1007/s10840-011-9601-1.CrossRefGoogle Scholar
- 16.Pedersen OD, Brendorp B, Elming H, Pehrson S, Køber L, Torp-Pedersen C. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) study. Card Electrophysiol Rev. 2003;7(3):220–4.CrossRefGoogle Scholar
- 23.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefGoogle Scholar